Pharmicell Co Ltd

005690

Company Profile

  • Business description

    Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

  • Contact

    12F Chungho B/D
    3-2 Nonhyun-dong Gangnam-gu
    Seoul135-010
    KOR

    T: +82 234960114

    http://www.pharmicell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    134

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,175.1049.900.61%
CAC 407,536.2633.480.45%
DAX 4022,242.45177.940.81%
Dow JONES (US)40,113.5020.100.05%
FTSE 1008,415.257.810.09%
HKSE21,980.7470.980.32%
NASDAQ17,382.94216.901.26%
Nikkei 22535,705.74666.591.90%
NZX 50 Index12,017.8461.370.51%
S&P 5005,525.2140.440.74%
S&P/ASX 2007,968.2047.700.60%
SSE Composite Index3,295.062.23-0.07%

Market Movers